Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application

Journal of Pharmaceutical and Biomedical Analysis

Volumn 51, Issue 4, 2010, Pages 958-964

  Zhou, Qingyu ^a   Gallo, James M ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

LC MS MS; Mouse intracerebral tumor model; Pharmacokinetics; Sunitinib

Indexed keywords

SUNITINIB;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; ELECTROSPRAY MASS SPECTROMETRY; GLIOMA; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MOUSE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN; BRAIN NEOPLASMS; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; GLIOMA; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; PYRROLES; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 72149114320     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.10.006     Document Type: Article

References (17)

1. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., and Cherrington J.M. SU11248 inhibits c-KIT and platelet-derived growth factor receptor-β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2 (2003) 471-478
2. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 2 (2007) 884-896
3. Faivre S., Demetri G., Sargent W., and Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6 (2007) 734-745
4. Britten C.D., Kabbinavar F., Hecht J.R., Bello C.L., Li J., Baum C., and Slamon D. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother. Pharmacol. 61 (2008) 515-524
5. Houk B.E., Bello C.L., Kang D., and Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin. Cancer Res. 15 (2009) 2497-2506
6. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., and Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
7. Patyna S., Haznedar J., Morris D., Freshwater K., Peng G., Sukbuntherng J., Chmielewski G., and Matsumoto D. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res., Part B 86 (2009) 204-213
8. Minkin P., Zhao M., Chen Z., Ouwerkerk J., Gelderblom H., and Baker S.D. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 874 (2008) 84-88
9. Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., and Decosterd L.A. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J. Chromatogr. B 877 (2009) 1982-1996
10. Barattè S., Sarati S., Frigerio E., James C.A., Ye C., and Zhang Q. Quantification of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J. Chromatogr. A 1024 (2004) 87-94
11. de Boüard S., Herlin P., Christensen J.G., Lemoisson E., Gauduchon P., Raymond E., and Guillamo J.S. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro. Oncol. 92 (2007) 412-423
12. Zhou Q., and Gallo J.M. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro. Oncol. 11 (2009) 301-310
13. Sun L., Liang C., Shirazian S., Zhou Y., Miller T., Cui J., Fukuda J.Y., Chu J.Y., Nematalla A., Wang X., Chen H., Sistla A., Luu T.C., Tang F., Wei J., and Tang C. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46 (2003) 1116-1119
14. Roskoski Jr. R. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 356 (2007) 323-328
15. Zhao Y., Sukbuntherng J., and Antonian L. Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 35 (2004) 513-522
16. Sistla A., Yang W.L., and Shenoy N. High-performance liquid chromatographic method for determination of reversible isomers of SU5416. J. Chromatogr. A 1110 (2006) 73-80
17. Song D., Wong W., and Giannousis P. To E or to Z, that's the question: an investigation of the E/Z-isomerization of SUGEN compounds. Proceedings of the AAPS Conference (November 2002)